Abstract: Multi-target drugs represent an innovative approach of medicinal chemistry. This approach contrasts with the "one goal, one drug" paradigm and is based on the concepts of privileged scaffolds, polypharmacology and multifactorial diseases. It appears to be a useful tool in the design of anti-invasive drugs, as the therapeutic agents designed in this way interact with multiple targets and thus prevent resistance or are able to destroy resistant pathogens/cells. Similarly, multi-target drugs can be designed for the simultaneous treatment of autoimmune and inflammatory diseases. Quinoline-based compounds have a wide range of promising biological properties; therefore, special attention is paid to them in drug design and medicinal chemistry. The quinoline scaffold can be easily and rapidly synthesized, which shows the importance of this privileged structure. In addition, this simple scaffold has unique physicochemical properties and provides the possibility of a large number of targeted modifications. This contribution is focused on effective anti-invasive agents derived from the hydroxyquinoline and aminoquinoline scaffolds.

Keywords: multi-target compounds, privileged scaffolds, quinolines

Biography: Josef Jampilek completed his Ph.D. degree in Medicinal Chemistry at the Faculty of Pharmacy of the Charles University (Czech Republic) in 2004. In 2004-2011, he worked in expert and managerial posts in the R&D Division of the pharmaceutical company Zentiva (Czech Republic). Prof. Jampilek deepened his professional knowledge at the Medicinal Chemistry Institute of the Heidelberg University (Germany) and at multiple specialized courses. In 2009, he became an Associate Professor of Medicinal Chemistry at the Faculty of Pharmacy of the University of Veterinary and Pharmaceutical Sciences Brno (Czech Republic). In 2017, he became a Full Professor of Medicinal Chemistry at the Faculty of Pharmacy of the Comenius University (Slovakia). He is an author/co-author of more than 30 patents/patent applications, more than 200 peer-reviewed scientific publications, 7 university textbooks, more than 30 chapters in monographs, and many invited lectures at international conferences and workshops. He also received several awards for his scientific results, e.g., from Aventis, Elsevier, Willey, Sanofi and FDA. The research interests of Prof. Jampilek include design, synthesis, and structure-activity relationships of heterocyclic compounds as anti-infectious, antiproliferative and anti-inflammatory agents as well as photosynthesis inhibitors. He is also interested in ADME, drug bioavailability and solid-state pharmaceutical analysis.